Scarica l'app Stockscreener
0.2016
15.62%
-0.0384
Precedente Chiudi:
$0.24
Aprire:
$0.2033
Volume 24 ore:
5.53M
Relative Volume:
0.76
Capitalizzazione di mercato:
$3.67M
Reddito:
-
Utile/perdita netta:
$-13.24M
Rapporto P/E:
-0.0228
EPS:
-8.83
Flusso di cassa netto:
$-16.85M
1 W Prestazione:
-19.64%
1M Prestazione:
-30.41%
6M Prestazione:
-75.17%
1 anno Prestazione:
-94.23%
Intervallo 1D:
$0.19
$0.2097
Intervallo di 1 settimana:
$0.19
$0.29
Portata 52W:
$0.19
$5.48
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
Nome
Virpax Pharmaceuticals Inc
Settore
Industria
Telefono
610-727-4597
Indirizzo
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
Confronta VRPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.2016 | 3.67M | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.10 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.58 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.08 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.11 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Virpax Pharmaceuticals Inc Borsa (VRPX) Ultime notizie
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com Australia
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data - TipRanks
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Virpax(R) Pharmaceuticals to Present at ThinkEquity Conference - ACCESS Newswire
Virpax Pharmaceuticals Advances Pain Management with Promising Probudur Study Results - MSN
Virpax reports positive study results for pain management drug - MSN
Breakthrough in Pain Relief: Virpax Pharmaceuticals Soars with US Army Collaboration - Bit Perfect Solutions
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Benzinga
Virpax reports positive study results for pain management drug By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur - TipRanks
Military Breakthrough: New Pain Control Drug Shows 96-Hour Combat Effectiveness in Army Tests - StockTitan
Promising Nanotechnology Stocks To Follow TodayFebruary 11th - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 08th - MarketBeat
Promising Nanotechnology Stocks To Watch TodayFebruary 06th - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 05th - MarketBeat
Promising Nanotechnology Stocks To Watch Today – February 06th - Armenian Reporter
Virpax Pharmaceuticals Inc (VRPX) Stock: What the Analysts are Saying - The News Heater
Virpax Pharmaceuticals Appoints Charn Deol as Independent DirectorVirpax Pharmaceuticals, Inc. (NASDAQ:VRPX) announced on February 5, 2025, the appointment of Mr. Charn Deol as an independent director of the Company, effective immediately. Mr. D - Defense World
Virpax Pharmaceuticals appoints new independent director By Investing.com - Investing.com Australia
Virpax Pharmaceuticals appoints new independent director - MSN
Virpax Pharmaceuticals Appoints Charn Deol as Independent Director - TipRanks
Virpax Pharmaceuticals director resigns due to compliance - MSN
Virpax Pharmaceuticals director resigns due to compliance By Investing.com - Investing.com Canada
Virpax Pharmaceuticals Board Member Jay Panis Resigns - TipRanks
Virpax Pharmaceuticals Highlights Leadership Contributions at Clinical Trial Conference - MSN
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Virpax Pharmaceuticals stock hits 52-week low at $0.29 - MSN
VRPXVirpax Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Clinical Trials Innovation: Virpax Leadership Takes Center Stage at Elite OCT Conference - StockTitan
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering - GlobeNewswire
Virpax Pharmaceuticals Raises $6M and Signs Investor Agreements - TipRanks
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering - The Manila Times
Virpax Pharmaceuticals Closes of $6.0 Million Public Offering of Common Stock - citybiz
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Virpax Pharmaceuticals Prices of $6 Million Public Offering of Common Stock - citybiz
Virpax Pharmaceuticals Announces $6 Mln Public Offering For Pain Relief Innovations - Nasdaq
Virpax Pharmaceuticals Inc Azioni (VRPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.34%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):